On July 22, 2020, Robert Ford, President and Chief Executive Officer of Abbott Laboratories, told investors that the company was poised to enter the U.S. market with a product that could potentially be a multi-billion dollar business.  According to Ford, the company has been investing heavily in its core diagnostics business, which includes core laboratory and molecular diagnostics.  In the second quarter of 2019, the company reported strong sales growth in core laboratory and molecular diagnostics, including double-digit growth in adult nutrition, including more than 20% growth in the second quarter of 2019.  In the third quarter, the company reported strong sales growth in core diagnostics, including core laboratory and molecular diagnostics.  The company also reported strong revenue growth in its core diagnostics business, including double-digit growth in core laboratory and molecular diagnostics.  In addition, the company reported strong revenue growth in core laboratory and molecular diagnostics in the second quarter of 2019.  The company's plans to expand its core diagnostics business, including core laboratory and molecular diagnostics, are still in the early innings.  The company's plans to expand the core diagnostics business, which includes core laboratory, core molecular diagnostics, and core laboratory and molecular diagnostics, are still being evaluated by the market.  The company is evaluating the options available to it.  The company is evaluating the options available for additional investment.  Robert Ford, President and Chief Executive Officer, and Scott Leinenweber, Vice President, Investor Relations, will lead the discussion.  The company appreciates the assistance of the U.S. Attorney's Office for the Southern District of New York, the Federal Bureau of Investigation, and the Financial Industry Regulatory Authority.